Cancer combo trial pulled before it even started

NCT ID NCT05982522

Terminated Disease control Sponsor: InxMed (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test a new oral drug called IN10018 combined with chemotherapy (nab-paclitaxel) and an immunotherapy (tislelizumab) in people with advanced solid tumors, specifically non-small cell lung cancer, that had stopped responding to prior treatments. The goal was to see if the combination could shrink tumors and to find the safest dose. However, the trial was withdrawn before enrolling any participants, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IN10018 (a drug taken by mouth) combined with nab-paclitaxel (chemotherapy) and tislelizumab (immunotherapy)
What this could lead to: If it works, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

More trials for these conditions

Other studies related to the condition(s) this trial covers.